AbbVie picks Singapore for a $320M production facility

Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis ($NVS), GlaxoSmithKline ($GSK) and Amgen ($AMGN). Even Russia's Pharmstandard has an API facility there. Now AbbVie ($ABBV) will join the group. The maker of Humira, the best-selling drug in the world, said Wednesday that it will invest $320 million to build its first facility in Asia. The plant will be designed for both small-molecule production and biologic active ingredients for AbbVie's oncology and immunology pipeline. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.